AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34799275 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized follitropin delta dosing
Number of subjects: 800
Study 33984356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 75
Study 33984356 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 75
Study 33984356 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Yoga and CBT
Number of subjects: 75
Study 35060389 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMI (<20 kg/m2; n=244)
Number of subjects: 15828
Study 35060389 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI (≥35 kg/m2; n=1768)
Number of subjects: 15828
Study 35060389 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI between 20 and <25 kg/m2
Number of subjects: 15828
Study 35060389 — intervention group
Group type: COMPARATOR
Intervention: BMI of 25 to 35 kg/m2
Number of subjects: 15828
Study 33144049 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAA (polaprezinc in polyacrylic acid solution)
Number of subjects: 120
Study 33144049 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PPAA)
Number of subjects: 120
Study 35512757 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylose-resistant starch (RS) supplementation, 16g/d for 4 weeks
Number of subjects: 25
Study 35512757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 35162761 — intervention group
Group type: EXPERIMENTAL
Intervention: Physio‐EndEA program (therapeutic exercise program focused on lumbopelvic stabilization and tolerance to exertion)
Number of subjects: 22
Study 35162761 — intervention group
Group type: EXPERIMENTAL
Intervention: Physio‐EndEA program
Number of subjects: 22
Study 35162761 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study 32312344 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 151
Study 32312344 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 151
Study 32312344 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram and Desvenlafaxine
Number of subjects: 151
Study 32018252 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 1223
Study 32018252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study 35157493 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of BNT162b2 vaccine
Number of subjects: 107413
Study 35157493 — intervention group
Group type: COMPARATOR
Intervention: No vaccination
Number of subjects: 107413
Study 34112656 — intervention group
Group type: COMPARATOR
Intervention: Usual escalation (5 mg every 4 weeks)
Number of subjects: 178
Study 34112656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast escalation (5 mg every 2 weeks)
Number of subjects: 178
Study 34112656 — intervention group
Group type: COMPARATOR
Intervention: Usual escalation
Number of subjects: 178
Study 34112656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast escalation
Number of subjects: 178
Study 32925765 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise training
Number of subjects: 192
Study 32925765 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (health education and Tiotropium bromide)
Number of subjects: 192
Study 36139001 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 2 mA)
Number of subjects: 20
Study 36139001 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 33225995 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly self-collected oral swabs (OS) regardless of symptoms
Number of subjects: 400
Study 33225995 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly self-collected oral-nares swab (O-NS) regardless of symptoms
Number of subjects: 400
Study 33225995 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly nurse collected nasopharyngeal swab (NPS) regardless of symptoms
Number of subjects: 400
Study 33225995 — intervention group
Group type: COMPARATOR
Intervention: Active daily surveillance of symptoms and testing only in symptomatic participants (comparator group)
Number of subjects: 400
Study 33225995 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention arms
Number of subjects: 400
Study 33029804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer closure technique
Number of subjects: 225
Study 33029804 — intervention group
Group type: COMPARATOR
Intervention: Double-layer closure technique
Number of subjects: 225
Study 35997003 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% mandibular advancement
Number of subjects: 32
Study 35997003 — intervention group
Group type: COMPARATOR
Intervention: 75% mandibular advancement
Number of subjects: 32
Study 34837992 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sutureless and glue-free method
Number of subjects: 52
Study 34837992 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 52
Study 32557731 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal invasive extracorporeal circulation (MiECC)
Number of subjects: 240
Study 32557731 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 240
Study 35779328 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 114
Study 35779328 — intervention group
Group type: COMPARATOR
Intervention: Sham control interview (CI)
Number of subjects: 114
Study 35779328 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who attended at least one training session (regardless of randomization)
Number of subjects: 114
Study 32446172 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory group-based care management
Number of subjects: 392
Study 32446172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 392
Study 35641327 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary new-generation stents
Number of subjects: 9204
Study 35109416 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital application-supported compensation training and lifestyle modification intervention
Number of subjects: 200
Study 35109416 — intervention group
Group type: COMPARATOR
Intervention: Education only control group (no use of EMMA app)
Number of subjects: 200
Study 32883322 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 5-day prednisone
Number of subjects: 0
Study 32883322 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 9-day prednisone
Number of subjects: 0
Study 32883322 — intervention group
Group type: EXPERIMENTAL
Intervention: JWBY formulas plus 5-day prednisone
Number of subjects: 0
Study 32883322 — intervention group
Group type: EXPERIMENTAL
Intervention: JWBY formulas plus 9-day prednisone
Number of subjects: 0
Study 34667294 — intervention group
Group type: EXPERIMENTAL
Intervention: CVN058 150 mg
Number of subjects: 22
Study 34667294 — intervention group
Group type: EXPERIMENTAL
Intervention: CVN058 (combined analysis across all MMN deviants)
Number of subjects: 22
Study 34667294 — intervention group
Group type: EXPERIMENTAL
Intervention: CVN058 (location MMN)
Number of subjects: 22
Study 34667294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34052211 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN using the Peregrine Kit with alcohol (0.6 mL per renal artery)
Number of subjects: 396
Study 34052211 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic renal angiography only (sham procedure)
Number of subjects: 396
Study 33135737 — intervention group
Group type: COMPARATOR
Intervention: LEAP238-47 infusion in healthy human individuals (n=10)
Number of subjects: 20
Study 33135737 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 20
Study 33135737 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP238-47
Number of subjects: 20
Study 32476624 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy-focused 'Quit' label
Number of subjects: 398
Study 32476624 — intervention group
Group type: COMPARATOR
Intervention: Threat-focused warning labels
Number of subjects: 398
Study 32476624 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy-focused 'Quit' label within a set of threat-focused labels
Number of subjects: 398
Study 35134170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (Trulicity) 1.5 mg
Number of subjects: 54
Study 35134170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 54
Study 33412128 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal and transperineal ultrasound assessments
Number of subjects: 344
Study 33412128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model developed from ultrasound assessments
Number of subjects: 344
Study 33969466 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of colorectal PM
Number of subjects: 0
Study 33969466 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized prognostic variables (Peritoneal Cancer Index, Completeness of Cytoreduction Score)
Number of subjects: 0
Study 33969466 — intervention group
Group type: COMPARATOR
Intervention: Second look surgery with oxaliplatin HIPEC
Number of subjects: 0
Study 33969466 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic oxaliplatin HIPEC
Number of subjects: 0
Study 33969466 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin HIPEC with CRS of colorectal PM
Number of subjects: 0
Study 33832544 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 203
Study 33832544 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 203
Study 32818525 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA, 30 min)
Number of subjects: 60
Study 32818525 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (2 mA, 30 min, 40 Hz frequency)
Number of subjects: 60
Study 32818525 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60
Study 36354718 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (100 mg adjunct testosterone, seven weekly injections)
Number of subjects: 24
Study 36354718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36354718 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 24
Study 32586361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral TQL block with 30 ml ropivacaine 0.375% each on both sides plus postoperative patient-controlled intravenous analgesia with morphine (TQL group, n=75)
Number of subjects: 150
Study 32586361 — intervention group
Group type: COMPARATOR
Intervention: Bilateral TQL block with 30 ml saline each on both sides plus postoperative patient-controlled intravenous analgesia with morphine (placebo group, n=75)
Number of subjects: 150
Study 32586361 — intervention group
Group type: EXPERIMENTAL
Intervention: TQL group
Number of subjects: 150
Study 34856563 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 59
Study 34856563 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 59
Study 33583740 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin administered 24 hours pre-operatively
Number of subjects: 340
Study 33583740 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin administered 48 hours pre-operatively
Number of subjects: 340
Study 33583740 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (250 mg/dose every 8 h x 3 doses beginning 1 h before surgery)
Number of subjects: 340
Study 33757937 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter with concurrent oxytocin administration
Number of subjects: 151
Study 33757937 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter only
Number of subjects: 151
Study 32367416 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral CT
Number of subjects: 503
Study 32367416 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 503
Study 36097565 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation (combination of TCM and Western conventional rehabilitation methods including acupuncture, repeated transcranial magnetic stimulation, traditional Chinese herbal medicine, and standard care)
Number of subjects: 188
Study 36097565 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation
Number of subjects: 188
Study 34321316 — intervention group
Group type: EXPERIMENTAL
Intervention: SCO-267 (GPR40 full agonist)
Number of subjects: 0
Study 33052382 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 997
Study 33052382 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 997
Study 33052382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997
Study 35857127 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy for metastatic breast cancer
Number of subjects: 0
Study 33568088 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score (PS) based on pTNM stage, number of lymph nodes (NLNs), and PD-L1 expression.
Number of subjects: 153
Study 33568088 — intervention group
Group type: COMPARATOR
Intervention: Prognostic score (PS) system
Number of subjects: 153
Study 36177837 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Pancreatectomy with Islet AutoTransplantation (TP-IAT)
Number of subjects: 61
Study 36177837 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticoduodenectomy (PD)
Number of subjects: 61
Study 35438799 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone opioid blockade
Number of subjects: 60
Study 35438799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32559272 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/d for 24 weeks)
Number of subjects: 127
Study 32559272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 34602349 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin (GC, 4 cycles)
Number of subjects: 23
Study 34602349 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles)
Number of subjects: 23
Study 34602349 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (mandatory minimum total dose of 270 mg/m2)
Number of subjects: 23
Study 34602349 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin-based chemotherapy (at least 4 cycles)
Number of subjects: 23
Study 34602349 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (full doses given in 1866 cycles, 88%)
Number of subjects: 23
Study 34191424 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved B-ultrasound method (B method)
Number of subjects: 64
Study 34191424 — intervention group
Group type: COMPARATOR
Intervention: Physicians' clinical experience (control group)
Number of subjects: 64
Study 35245813 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EMG biofeedback
Number of subjects: 15
Study 35245813 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback
Number of subjects: 15
Study 35245813 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal cues biofeedback
Number of subjects: 15
Study 32723264 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg sublingual melatonin the evening before and 1 hour before surgery
Number of subjects: 76
Study 32723264 — intervention group
Group type: COMPARATOR
Intervention: Control group (no melatonin)
Number of subjects: 76
Study 32773013 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643
Study 32773013 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1643
Study 32773013 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 1643
Study 32773013 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1643
Study 35686812 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ablation therapy (AT)
Number of subjects: 2276
Study 35686812 — intervention group
Group type: COMPARATOR
Intervention: Partial nephrectomy (PN)
Number of subjects: 2276
Study 34096894 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole treatment
Number of subjects: 228
Study 34096894 — intervention group
Group type: COMPARATOR
Intervention: Exemestane treatment
Number of subjects: 228
Study 32198638 — intervention group
Group type: EXPERIMENTAL
Intervention: Top Surgery Scar go (Group A)
Number of subjects: 30
Study 32198638 — intervention group
Group type: COMPARATOR
Intervention: Silicone gel (Group B)
Number of subjects: 30
Study 32658597 — intervention group
Group type: COMPARATOR
Intervention: Traditional 1RM testing (BT)
Number of subjects: 70
Study 32658597 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel technique (TDT)
Number of subjects: 70
Study 32489264 — intervention group
Group type: EXPERIMENTAL
Intervention: elcss-ql arm (real-time electronic Lung Cancer Symptom Scale data provided to oncologists)
Number of subjects: 95
Study 32489264 — intervention group
Group type: COMPARATOR
Intervention: standard arm (standard clinical assessment without elcss-ql data)
Number of subjects: 95
Study 32489264 — intervention group
Group type: EXPERIMENTAL
Intervention: elcss-ql arm
Number of subjects: 95
Study 32489264 — intervention group
Group type: COMPARATOR
Intervention: standard arm
Number of subjects: 95
Study 35963369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivarmacitinib 8 mg QD
Number of subjects: 164
Study 35963369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivarmacitinib 4 mg BID
Number of subjects: 164
Study 35963369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivarmacitinib 4 mg QD
Number of subjects: 164
Study 35963369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 33151422 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 2% articaine
Number of subjects: 2
Study 33151422 — intervention group
Group type: COMPARATOR
Intervention: Non-buffered 4% articaine
Number of subjects: 2
Study 32097388 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 840
Study 32097388 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 840
Study 32097388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCI and CABG
Number of subjects: 840
Study 35457509 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV knowledge
Number of subjects: 382
Study 35457509 — intervention group
Group type: EXPERIMENTAL
Intervention: CHB-management motivation
Number of subjects: 382
Study 32889329 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch injury
Number of subjects: 150
Study 32889329 — intervention group
Group type: COMPARATOR
Intervention: Control (no endometrial scratch injury)
Number of subjects: 150
Study 35061166 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) intervention
Number of subjects: 102
Study 35061166 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group (typical EHS services)
Number of subjects: 102
Study 33620725 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive interventions
Number of subjects: 0
Study 33620725 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 32206810 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart age + conventional risk communication (intervention)
Number of subjects: 378
Study 32206810 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk communication (control)
Number of subjects: 378
Study 32206810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 378
Study 35920250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose magnesium sulfate solution (MSS)
Number of subjects: 1174
Study 35920250 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene glycol (PEG)
Number of subjects: 1174
Study 32533045 — intervention group
Group type: EXPERIMENTAL
Intervention: General Sleep Disturbance Scale (GSDS-IT)
Number of subjects: 57
Study 32533045 — intervention group
Group type: COMPARATOR
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 57
Study 35082252 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention mindfulness
Number of subjects: 153
Study 35082252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham
Number of subjects: 153
Study 35082252 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 153
Study 35082252 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation for pain relief (told mindfulness)
Number of subjects: 153
Study 35082252 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief of receiving mindfulness
Number of subjects: 153
Study 35082252 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy
Number of subjects: 153
Study 33168369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 98
Study 33168369 — intervention group
Group type: COMPARATOR
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 98
Study 32070395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered at a loading dose of 1 g, followed by 1 g every 8 hours for a maximum of 24 hours, in addition to standard care.
Number of subjects: 0
Study 32070395 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 32070395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 33555824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen rich water (HRW)
Number of subjects: 12
Study 33415606 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscotrabeculotomy
Number of subjects: 148
Study 33415606 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 148
Study 34311533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastiha
Number of subjects: 0
Study 34311533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35859928 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IL6_0 (≥3.67 pg/mL)
Number of subjects: 135
Study 35859928 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum TNFα_0 (≥14.8 pg/mL)
Number of subjects: 135